VPC-18005 inhibits ERG-induced transcription and interacts directly with the ERG-ETS domain , and disrupts the ERG binding to DNA. VPC-18005 is a potent inhibitor of luciferase activity.
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > DNA/RNA Synthesis
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.